COMMUNIQUÉS West-GlobeNewswire

Persephone Biosciences Announces Full Enrollment in AMBROSIA Food as Medicine Study
28/01/2025
- 400 participants with a medium-to-high risk of developing colorectal cancer (CRC) have been enrolled across two arms - - AMBROSIA is studying how diet quality and changes in diet resulting from Medical Nutrition [...]
Precision Optics Launches Revolutionary Unity Imaging Platform
28/01/2025
GARDNER, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation (Nasdaq: POCI), a global leader in the design and development of optical components and systems for advanced medical, industrial, and [...]
Sharps Technology, Inc. Announces Pricing of Upsized $20.0 Million Underwritten Public Offering
28/01/2025
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, [...]
Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions
28/01/2025
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Better Choice Company Signs Non-Binding Term Sheet to Sell Halo Asia for $6.5 Million in Cash at Closing and a 5-Year Royalty Valued at a Minimum of $1.65 Million
28/01/2025
Upon closing, Better Choice will retain ownership of North American and rest-of-world ex Asia operations Buyer has paid a $500,000 non-refundable deposit to purchase the assets in Asia TAMPA, Fla., Jan. 28, 2025 (GLOBE [...]
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
28/01/2025
Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of [...]
New Survey from Aeroflow Sleep Reveals Disparities Around Women’s Sleep Health
28/01/2025
The proprietary survey found 60% of women feel their sleep is negatively impacting their day-to-day activities, yet more than half have never spoken to their doctor about their sleep health ASHEVILLE, N.C., Jan. 28, [...]
Progyny, Inc. Enhances Suite of Services with Acquisition of BenefitBump
28/01/2025
Provides expecting parents with a concierge-level service model that delivers expert guidance, navigation and support for parental leave planning NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY [...]
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
28/01/2025
Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications Innovative Dagger ® Technology: Empowers ALLO [...]
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
28/01/2025
Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumors CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies [...]
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
28/01/2025
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to [...]
Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation
28/01/2025
One of the largest US outpatient medical imaging providers to introduce Xenon MRI platform to its network DURHAM, NC and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “ [...]
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
28/01/2025
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirement Evaxion has currently restored its equity above the [...]
FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY
28/01/2025
MINNEAPOLIS, MN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), provides a brief shareholder letter from Seamus Lagan, recently appointed CEO of FOXO on what has been [...]
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
28/01/2025
Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings. [...]
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
28/01/2025
Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating [...]
Lighthouse Autism Center Announces New Location in South Sioux City, Nebraska, creating 35 Jobs and Serving 25 Families
28/01/2025
Leading ABA Provider Set to Open Newest Location in South Sioux City, NE SOUTH SIOUX CITY, Neb., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Lighthouse Autism Center, South Sioux City, Nebraska, a leading provider of center-based [...]
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
28/01/2025
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
28/01/2025
Appoints Simon Harnest as Chief Financial Officer to advance capital markets and corporate development strategy supporting TOS-358, the Company’s lead covalent PI3Kα inhibitor, and additional programs EMERYVILLE, Calif [...]

Pages